UroGen Pharma Ltd. Enters Option Agreement with IntraGel; $7M Investment

What Happened UroGen Pharma Ltd. reported on Aug 20, 2026 (event dated Aug 18, 2026) that its U.S. subsidiary, UroGen Pharma, Inc., entered an Option and Research License Agreement with IntraGel Therapeutics, Ltd. Under the agreement UroGen U.S. obtained an exclusive option to license IntraGel’s TumoCure product formulated with IntraGel’s biodegradable hydrogel sustained‑release delivery platform (the “SRGel platform”) for the treatment of advanced head and neck cancer, plus options to license additional SRGel‑based products and a non‑exclusive research license to evaluate the platform. Concurrently, UroGen agreed to a Securities Purchase Agreement to invest up to $7,000,000 in IntraGel equity.

Key Details

• Agreement and investment announced in an 8-K filed Aug 20, 2026; deal signed Aug 18, 2026.
• UroGen U.S. received an exclusive option for a worldwide license to develop/commercialize TumoCure with IntraGel’s SRGel for advanced head and neck cancer.
• Additional options cover exclusive, worldwide licenses to combine the SRGel platform with compounds designated by UroGen.
• UroGen agreed to invest up to $7,000,000 in IntraGel equity under a Securities Purchase Agreement.

Why It Matters This is a business development and R&D collaboration, not an immediate product acquisition. For investors, the agreement gives UroGen potential rights to a new delivery platform (SRGel) and a candidate (TumoCure) focused on advanced head and neck cancer, which could expand UroGen’s oncology pipeline if options are exercised and licenses executed. The up‑to $7M equity investment signals a financial stake and partnership alignment with IntraGel but does not guarantee further milestones, approvals, or revenue—those would depend on future development, licensing decisions, and regulatory progress.